SCHEMBL3244575

SCHEMBL3244575

CCOC(=O)CCNS(=O)(=O)c1ccc2[nH]c(=O)c3[nH]cc(C(=O)OCC)c3c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HSD17B10 Q99714 2/20 0.39
HPGD P15428 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
GABRA1 P14867 2/20 0.39
GABRB2 P47870 2/20 0.39
BRAF P15056 2/20 0.39
GABRB1 P18505 1/20 0.38
GABRA3 P34903 1/20 0.38
LMNA P02545 2/20 0.38
TP53 P04637 2/20 0.38
MAPT P10636 2/20 0.38
CLEC4M Q9H2X3 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3249264 0.93 POLB (0.49) POLBTDP1KDM4EL3MBTL1ALDH1A1
SCHEMBL3245998 0.88 KDM4E (0.41) POLBTDP1KDM4EL3MBTL1ALDH1A1
SCHEMBL3249820 0.87 BRAF (0.49) POLBTDP1KDM4EL3MBTL1ALDH1A1
SCHEMBL3248963 0.87 TAS2R14 (0.44) KDM4EL3MBTL1ALDH1A1MEN1KMT2A
SCHEMBL3251387 0.86 POLB (0.40) POLBTDP1KDM4EL3MBTL1ALDH1A1
SCHEMBL4157985 0.85 KDM4E (0.39) POLBTDP1KDM4EL3MBTL1ALDH1A1
SCHEMBL3242035 0.84 GABRA1 (0.45) POLBKDM4EL3MBTL1ALDH1A1MEN1
SCHEMBL3244720 0.83 GABRA1 (0.44) POLBKDM4EL3MBTL1ALDH1A1MEN1
SCHEMBL3250602 0.83 PARG (0.50) POLBTDP1KDM4EALDH1A1MEN1
SCHEMBL3254789 0.83 PKM (0.51) POLBTDP1KDM4EALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1899335-B1 PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS PF MEDICAMENT (FR) 2010-05-19 EP claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 POLB 1007/4885TDP1 1098/4885KDM4E 1970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.